Suggested remit - To appraise the clinical and cost effectiveness of filgotinib within its marketing authorisation for treating moderate to severe rheumatoid arthritis
 
Status Proposed
Process STA 2018
ID number 1632

Provisional Schedule

Committee meeting 07 October 2020

Project Team

Project lead Gemma Barnacle

Email enquiries

Consultees

Companies sponsors Gilead (filgotinib)
Others Department of Health and Social Care
  NHS England
  NHS Lambeth CCG
  NHS Waltham Forest CCG
  Welsh Government
Patient carer groups Action on Pain
  Arthritis Action
  Arthritis and Musculoskeletal Alliance
  Back Care
  Muslim Council of Britain
  National Rheumatoid Arthritis Society
  Pain Concern
  Pain Relief Foundation
  Pain UK
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Versus Arthritis
Professional groups British Geriatrics Society
  British Institute of Musculoskeletal Medicine
  British Orthopaedic Association
  British Pain Society
  British Society for Rheumatology
  British Society of Rehabilitation Medicine
  Chartered Society for Physiotherapy
  Physiotherapy Pain Association
  Primary Care Rheumatology Society
  Rheumatoid Arthritis Surgical Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Occupational Therapists
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society and College of Radiographers
  UK Clinical Pharmacy Association

Commentators

Associated public health groups Public Health England
  Public Health Wales
Comparator companies Abbvie (adalimumab)
  Accord Healthcare (methotrexate)
  Advanz Pharma (methotrexate)
  Amgen (adalimumab biosimilar)
  Aspire Pharma (leflunomide)
  Biogen (adalimumab biosimilar, etanercept biosimilar, infliximab biosimilar)
  Bristol Laboratories (hydroxychloroquine)
  Bristol-Myers Squibb (abatacept)
  Cipla (methotrexate)
  Eli Lilly (baricitinib)
  Hospira (methotrexate)
  medac (leflunomide, methotrexate)
  Merck Sharp & Dohme (golimumab, infliximab)
  Mylan (adalimumab biosimilar, leflunomide)
  Napp (rituximab biosimilar, infliximab biosimilar)
  Nordic Pharma (methotrexate)
  Orion Pharma (methotrexate)
  Pfizer (infliximab biosimilar, tofacitinib, etanercept, methotrexate, sulfasalazine)
  Roche (tocilizumab, rituximab)
  Rosemont Pharmaceuticals (methotrexate, sulfasalazine)
  Sandoz (adalimumab biosimilar, rituximab biosimilar, etanercept biosimilar, infliximab biosimilar methotrexate, leflunomide)
  Sanofi (hydroxychloroquine, leflunomide, sarilumab)
  Therakind (methotrexate)
  UCB Pharma (certolizumab pegol)
  Zentiva (hydroxychloroquine, leflunomide)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Bone Research Society
  Chronic Pain Policy Coalition
  Cochrane Musculoskeletal Group
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research
  Orthopaedic Research UK
  Pain Relief Foundation
  Society of Back Pain Research

Timeline

Key events during the development of the guidance:

Date Update
03 April 2020 Topic update: this appraisal has not been defined as therapeutically critical (please follow the link titled rapid guidelines and evidence summaries within the yellow banner at the top of the page for information on recent changes to the way we work). The appraisal will therefore be paused. At this stage, we are unable to provide alternative timelines as to when the appraisal may be re-started but we will provide updates as and when this information becomes clear.
06 February 2020 Invitation to participate
01 October 2019 - 29 October 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance